TACSTD2 and prostate carcinoma: These findings suggest that TROP2 may play a role in the ability of androgen-sensitive, but not of androgen-independent prostate cancer cells, to avoid cell death and/or to recover from treatment following exposure to high concentrations of chemotherapeutics.